Laurion Capital Management LP acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 2,457,189 shares of the company's stock, valued at approximately $16,611,000. Laurion Capital Management LP owned 0.63% of Recursion Pharmaceuticals at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of RXRX. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $26,000. Private Trust Co. NA purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $27,000. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after buying an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Stock Performance
Shares of NASDAQ RXRX traded up $0.31 during mid-day trading on Friday, hitting $4.56. The company had a trading volume of 22,410,503 shares, compared to its average volume of 13,175,070. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -2.98 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm's 50 day simple moving average is $5.34 and its two-hundred day simple moving average is $6.59.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the business posted ($0.39) EPS. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Analyst Ratings Changes
RXRX has been the subject of a number of recent research reports. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley decreased their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Needham & Company LLC cut their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $7.60.
Read Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Company Profile
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
